Login to Your Account

Shipment of Stivarga Begins Friday

Bayer, Onyx Win Quick FDA Approval on Stivarga in mCRC

By Marie Powers
Staff Writer

Friday, September 28, 2012
Bayer HealthCare Pharmaceuticals wasted no time moving the oral multikinase inhibitor Stivarga (regorafenib) to market in metastatic colorectal cancer (mCRC) following FDA approval Thursday morning.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription